louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03591198: Improving Health and Reducing Disability of Depressed Elderly With Chronic Conditions Through Qigong Exercise
Official title: Improving Health and Reducing Disability of Depressed Elderly With Chronic Conditions Through Qigong Exercise: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Disease
Depressive Symptoms
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
Collaborators: name: Fujian University of Traditional Chinese Medicine
First posted: 2018-07-19
Enrollment: 47
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Qigong exercise is beneficial for older adults with co-occurring chronic physical illness and depression in terms of psychological and physical outcomes. However, the effects on functional independence, sleep quality, and mobility of depressive older adults remain unclear. It is also important to replicate its benefits for subjective well-being and muscle strength. A randomized clinical trial was conducted among older adults who were aged 60 or above and with chronic medical conditions for one year. After random assignment, intervention group (n = 25) went through qigong exercise twice a week and for 12 weeks,whereas control group (n = 22) was involved in cognitive training activities with mobilization elements. The psychosocial and physical outcomes of the two groups were compared.


Eligibility criteria: Inclusion Criteria:

* aged 60 or above
* have been suffering from chronic medical conditions for more than one year
* have depressive symptoms as indicated by Geriatric Depression Scale (GDS ≥ 6)

Exclusion Criteria:

* have practiced or received training of any form of mind-body exercises (including tai chi, yoga, and qigong) during the 6 months prior to intervention.
* have changed medication or the dosage prior to or during intervention
* have obvious cognitive and language impairment or score less than 20 in Mini-Mental State Examination (MMSE)
* undergo electroconvulsive therapy, psychotherapy, or psychoeducation
* cannot demonstrate satisfactory sitting balance

Primary outcomes:
measure: Personal Well-Being Index (PWI)
timeFrame: the change from baseline to the completion of intervention (12 weeks later)
Secondary outcomes:
measure: Functional Independence Measure (FIM)
timeFrame: baseline, 12 weeks after baseline, and 16 weeks after baseline
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: baseline, 12 weeks after baseline, and 16 weeks after baseline
measure: Timed up and Go Test (TUG)
timeFrame: baseline, 12 weeks after baseline, and 16 weeks after baseline
measure: Handgrip Strength
timeFrame: baseline, 12 weeks after baseline, and 16 weeks after baseline
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: The Hong Kong Polytechinic University
Study officials:
References:
Clinical trial NCT06519305: Examination of Musculoskeletal System Problems, Pain and Quality of Life Related to Working Conditions in Chiropractors
Official title: Examination of Musculoskeletal System Problems, Pain and Quality of Life Related to Working Conditions in Chiropractors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Musculoskeletal Problems, Pain, and QoL in Chiropractors in Relation to Their Working Conditions
Keywords: musculoskeletal system problems,
pain,
quality of life,
chiropractors
Lead sponsor: Istanbul Bilgi University
Sponsor class: OTHER
First posted: 2024-07-25
Enrollment: 30
Sex: ALL
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Professionals actively working as chiropractors

Brief summary: This research aims to investigate musculoskeletal problems and pain, as well as their effects on the quality of life, arising from the working conditions of chiropractors in their workplaces. Additionally, it is intended to conduct a detailed analysis of working conditions in chiropractors' work environments to identify existing problems, establish the cause-and-effect relationship between musculoskeletal problems, pain, and these conditions, conduct studies to improve chiropractors' work environments, and demonstrate the positive effects of improving working conditions on the quality of life and professional performance of chiropractors. Within this scope, the physical layout of chiropractors' work environments, ergonomic factors, and workplace conditions will be analyzed. Musculoskeletal problems experienced by chiropractors will be identified, and research will be conducted on pain and musculoskeletal disorders associated with workplace factors. Furthermore, the effects of working conditions on the quality of life of chiropractors will be evaluated.


Eligibility criteria: Inclusion Criteria:

* Male and female physiotherapists between the ages of 25-45, with at least 1 year of chiropractic experience, will be selected

Exclusion Criteria:

* Having practiced chiropractic for less than 1 year.

Primary outcomes:
measure: The Visual Analog Scale (VAS)
timeFrame: 1 mount
measure: SF-36 Short Form 36 Health Survey,
timeFrame: 1 mount
Secondary outcomes:
measure: The Beck Depression Inventory (BDI)
timeFrame: 1 mount
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Bilgi University
Study officials:
References:
Clinical trial NCT04909905: Glutamine Supplementation and Short-term Mortality in Covid-19
Official title: The Impact of Glutamine Supplementation Upon the Short-term Mortality of COVID-19 Diseased Patients Admitted in ICU: A Double Blind Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Covid19
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2021-06-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to investigate the effect of parenteral L-Glutamine supplementation added to enteral nutrition on short-term ICU mortality (7 days) in Covid-19 diseased patients.

Detailed description: A written informed consent will be taken from the patients or their relatives. Patients with diagnosis of covid-19 with enteral nutrition will be enrolled. Patients will be randomly assigned to receive either standard enteral nutrition (Group EN) or intravenous glutamine supplementation to enteral nutrition (group GN) in a dose of glutamine of 0.4 g/kg/day during ICU stay.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of covid-19 diseased patients admitted to the ICU with enteral nutrition.

Exclusion Criteria:

* Renal failure (creatinine \>180 mmol/l)
* Hepatic failure (bilirubin \>40 mmol/l, alanine aminotransferase \>100 U/l and aspartate aminotransferase \>100 U/l)
* Severe neutropenia (\<500 cells/mm3)
* Patients receiving cytotoxic, radiation and/or steroid therapy
* Hemodynamic instability

Primary outcomes:
measure: ICU mortality
timeFrame: 7 days
Secondary outcomes:
measure: Neutrophil/lymphocyte ratio (NLR)
timeFrame: 7 days
measure: D- dimer level
timeFrame: 7 days
measure: ICU stay
timeFrame: 7 days
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Omar Soliman
state: Assuit
Study officials:
affiliation: Omar makram
name: Omar Soliman, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mehta S. Nutritional status and COVID-19: an opportunity for lasting change? Clin Med (Lond). 2020 May 15;20(3):270-273. doi: 10.7861/clinmed.2020-0187.
Clinical trial NCT05133505: Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas
Official title: Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lymphoma, B-Cell
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2021-11-24
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patient of Primary central nervous system diffuse large B cell lymphoma

Brief summary: Primary central nervous system diffuse large B cell lymphoma is a rare and aggressive entity of diffuse large B cell lymphoma. A previous transcriptomic study showed an overexpression of TIM-3 and Gal-9 in the tumor microenvironment. The investigators aimed to characterise TIM-3/Gal-9 immune checkpoints by using immunohistochemistry in the tumor microenvironment of primary central nervous system diffuse large B cell lymphoma.


Eligibility criteria: Inclusion criteria:

- patient with a Diagnosis of LBDGC-SNC

Exclusion criteria:

* immunocompromised patients
* patients with a history of previous or associated low-grade lymphoma
* patients with a history of systemic LBDGC with secondary localization to the SNC

Primary outcomes:
measure: TIM-3 and Gal-9 immunohistochemical expression
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uh Montpellier
Study officials:
affiliation: University Hospital, Montpellier
name: aline desrumaux, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02382705: SB3 Battery Life Observational Study
Official title: Clinical Impact of Longer Battery Life on Small Bowel Capsule Endoscopy: a Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Capsule Endoscopy
Keywords: capsule endoscopy
battery life
completion rate
diagnostic yield
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2015-03-09
Enrollment: 57
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing small bowel capsule endoscopy

Brief summary: Capsule endoscopy (CE) is a non-invasive means of visualizing the small bowel. Common indications for CE include obscure gastrointestinal (GI) bleeding, inflammatory bowel disease like crohn's disease or ulcerative colitis, celiac disease, and polyposis syndrome.

While CE has high diagnostic value for small bowel lesions, a significant limitation of this technology is the finite battery life which results in incomplete examination of the small bowel approximately 16.5% of the time. Numerous attempts of using pharmacological (e.g. prokinetics, purgatives) as well as non-pharmacological measures (e.g. real-time viewer, chewing gum) to improve completion rates, defined by entry of CE into the cecum, led to mixed results. Currently routine use of prokinetics (agents that speeds up gut motility) is not recommended.

This study aims to determine whether longer battery of the newer generation capsule endoscopy system improves study completion rate and diagnostic yield.


Eligibility criteria: Inclusion Criteria:

* Male or female age 19 or greater who are referred for small bowel capsule endoscopy
* Willing and able to provide written informed consent

Exclusion Criteria:

* Unwillingness or inability to swallow pill
* Known or suspected obstruction or bowel stricture
* Endoscopic placement of capsule camera
* Concomitant enrollment in a prospective study in the treatment arm receiving prokinetics for the purpose of enhancing bowel motility. (i.e. control arm not receiving any motility-enhancing agent can be included)

Primary outcomes:
measure: Completion Rate (Rate at Which Small Bowel is Completely Examined)
timeFrame: 0.1 - 12 hours
Secondary outcomes:
measure: Diagnostic Yield
timeFrame: 0.1 - 12 hours
measure: Gastric Transit Time
timeFrame: 0.1 - 12 hours
measure: Small Bowel Transit Time
timeFrame: 0.1 - 12 hours
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: St. Paul's Hospital
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Robert Enns, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01726205: Perioperative Pregabalin and Continuous Wound Infusion for Pain Control Following Thoracotomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Post-thoracotomy Pain
Lead sponsor: Attikon Hospital
Sponsor class: OTHER
First posted: 2012-11-14
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy of pregabalin or pregabalin and continuous wound infusion versus placebo for analgesia following thoracotomy


Eligibility criteria: Inclusion Criteria:

* patients scheduled for a thoracotomy,

Exclusion Criteria:

* age \>70 years
* BMI \> 30
* preoperative Hb \< 10 mg/dL
* preexistent chronic pain
* neurologic disease
* chronic assumption of alcohol
* treatment with analgesics, anxiolytics, sedatives, antidepressants, or calcium channel inhibitors

Primary outcomes:
measure: Pain control
timeFrame: 5 days postoperatively
Secondary outcomes:
measure: morphine consumption
timeFrame: 3 days postoperatively
Other outcomes:
measure: side effects, pain at 1 and 3 months, incidence of neuropathic pain
timeFrame: 3 months
Locations:
city: Athens
country: Greece
facility: Attikon Hospital
Study officials:
affiliation: Attikon Hospital
name: Tatiana Sidiropoulou
role: PRINCIPAL_INVESTIGATOR
affiliation: Attikon Hospital
name: Eyaggelos Giavasopoulos
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02624505: Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma
Official title: To Compare the Bronchoprotective Effects of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Methacholine Bronchoprovocation Challenge Testing in Stable Mild Asthma Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Bronchial Asthma
Lead sponsor: Cipla Ltd.
Sponsor class: INDUSTRY
First posted: 2015-12-08
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product, using bronchoprovocation (methacholine challenge testing) in adult patients with stable mild asthma.

Detailed description: This study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product in terms of FEV1 measured at different time-points, using bronchoprovocation (methacholine challenge testing) in adult patients with stable mild asthma.

Eligibility criteria: Inclusion Criteria:

* Male and non-pregnant female subjects (18-65 years of age)
* Forced Expiratory Volume in 1 second (FEV1) ≥ 80% of predicted. Airway responsiveness to methacholine demonstrated by a pre-albuterol dose (baseline) PC20 ≤ 8 mg/ml.
* Stable mild asthmatics based on National Asthma Education and Prevention Program (NAEPP) guidelines.
* Nonsmokers for at least 6 months prior to the study and a maximum smoking history of five pack-years (the equivalent of one pack per day for five years).
* Written informed consent.

Exclusion Criteria:

* Conditions which could alter airway reactivity to methacholine (e.g., pneumonia, upper respiratory tract infection, viral bronchitis and/or sinobronchitis) within six weeks prior to the screening visit.
* History of seasonal asthma exacerbations, in which case the patient should be studied outside of the relevant allergen season.
* History of a clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia.
* History of cystic fibrosis, bronchiectasis or other respiratory diseases other than Asthma
* Historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases
* Known intolerance or hypersensitivity or hypersensitivity to any component of the albuterol metered dose inhaler (MDI).

Primary outcomes:
measure: Provocative Concentration of Methacholine Causing 20 % Fall (PC20) in FEV1(Forced Expiratory Volume in 1 second)
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: Colorado Allergy and Asthma Centers
state: Colorado
Study officials:
affiliation: Cipla Ltd.
name: Dhiraj Abhyankar
role: STUDY_CHAIR
References:
Clinical trial NCT06887205: Immediate Lymphatic Reconstruction After Lymphadenectomy in Melanoma Patients: a Parallel Cohort Pilot Study
Official title: Immediate Lymphatic Reconstruction After Lymphadenectomy in Melanoma Patients: a Parallel Cohort Pilot Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Lymphatic Reconstruction
Lymphadenectomy
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2025-03-20
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To learn if LBP can help to prevent lymphedema when it is performed at the time of surgery rather than after a patient has already developed the disease.

Detailed description: To examine if performing lymphovenous bypass (LVB) at the time of axillary lymph node dissection (ALND) or inguinal lymph node dissection (ILND) in the melanoma participant population impacts the period prevalence of lymphedema occurrence one year from surgery. To assess wound complications rates occurring in first 30-days post operatively from the time of surgery. To estimate time to drain removal. To estimate the point prevalence of LE following surgery at 3 months, 6 months, and 1 year following surgery. To estimate the cumulative incidence associated with the first appearance of LE. To assess quality of life and survivorship, using Lymphedema Quality of Life (LYMQOL) questionnaire over the study follow-up domain.

Eligibility criteria: Inclusion Criteria:

1. Participants greater than or equal to 18 years of age.
2. Participants willing to participate.
3. Participants able to complete informed consent.
4. Participants with a diagnosis of Melanoma undergoing ALND or ILND.

Exclusion Criteria:

1. Participant staking anticoagulants within 7 days prior to surgery.
2. Participants that are known to be pregnant at the time of surgery.
3. Participants with BMI greater than 50.0

Primary outcomes:
measure: Safety and adverse events
timeFrame: Through study completion; an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Ashleigh M Francis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04896905: Rehabilitation After Covid19-Clinical Results and Predictive Factors
Official title: Rehabilitation After Covid19-Clinical Results and Predictive Factors for Rehabilitation Outcomes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Keywords: Covid19
Sars-CoV-2
Rehabilitation
Outcome
Predictive factors
Lead sponsor: Klinik Valens
Sponsor class: OTHER
First posted: 2021-05-21
Enrollment: 101
Sex: ALL
Minimum age (years): 40
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: All patients referred to rehabilitation between March and June 2020 either with active Covid19, post-Covid-State oor other indications for inpatient rehab (eg. muskuloskelettal, cancer, pulmonary diseases not related to Covid19)

Brief summary: The aim of the study is to gain insight into the rehabilitation process and predictive factors for the outcome after rehabilitation in three patient groups:

1. SARS-CoV-2-positive patients in the isolation ward
2. Post-Covid-19 patients
3. Control group; matched for gender, age and co-morbidity


Eligibility criteria: Inclusion Criteria:

* Patients assigned to rehab
* Written informed consent

Exclusion Criteria:

* not able to fill in questionnaires in German

Primary outcomes:
measure: Mobility
timeFrame: Measurements done at entry and at discharge of rehabilitation (time between: 4- 6 weeks)
measure: Functional Independence Measurement-Level (FIM)
timeFrame: Measurements done at entry and at discharge of rehabilitation (time between: 4- 6 weeks)
measure: Promis-10 (Promis= Patient reported outcome measurement information system)
timeFrame: Measurements done at entry and at discharge of rehabilitation (time between: 4- 6 weeks)
measure: Quality of life
timeFrame: Measurements done at entry and at discharge of rehabilitation (time between: 4- 6 weeks)
Secondary outcomes:
Other outcomes:
Locations:
city: Valens
country: Switzerland
facility: Rehabilitationszentrum Klinik Valens
state: SG
Study officials:
affiliation: Kliniken Valens
name: Steffi Petzold, MMed
role: PRINCIPAL_INVESTIGATOR
affiliation: Kliniken Valens
name: Roisin Carney, PT, cand MSc
role: PRINCIPAL_INVESTIGATOR
References: